|Application ||WB, IHC-P, IF, E|
|Other Accession||NP_001138985, 224465194|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||46382 Da|
|Application Notes||SCRN1 antibody can be used for detection of SCRN1 by Western blot at 1 µg/mL. Antibody can also be used for immunohistochemistry starting at 5 µg/mL. For immunofluorescence start at 20 µg/mL.|
|Reconstitution & Storage||SCRN1 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||SCRN1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Regulates exocytosis in mast cells. Increases both the extent of secretion and the sensitivity of mast cells to stimulation with calcium (By similarity).|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
SCRN1 Antibody: SCRN1 was first identified as a cytosolic protein that is involved in the regulation of exocytosis from peritoneal mast cells. More recent studies have shown that SCRN1 expression is upregulated in gastric cancer cell lines and may possess epitopes that could function as tumor-associated antigens, potentially providing targets for cancer vaccines in the treatment of gastric cancers. Another report indicates that decreased expression of SCRN1 via RNAi expression resulted in significantly lower rates of cell growth in colorectal cancer cell lines, and increased SCRN1 expression in patients with colorectal cancer correlated with poor prognosis, suggesting that SCRN1 may also be involved in the regulation of cell growth and might be useful as a prognostic tool.
Way G, Morrice N, Smythe C, et al. Purification and identification of Secernin, a novel cytosolic protein that regulates exocytosis in mast cells. Mol. Biol. Cell2002; 13:3344-54.
Suda T, Tsunoda T, Uchida N, et al. Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray. Cancer Sci.2006; 97:411-9.
Miyoshi N, Ishii H, Mimori K, et al. SCRN1 is a novel marker for prognosis in colorectal cancer. J. Surg. Oncol.2010; 101:156-9.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.